Companies › Ardelyx
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology, Gastroenterology, Respiratory; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tenapanor Sodium/hydrogen exchanger 3 inhibitor | SLC9A3 | Phase 3 | Chronic Idiopathic Constipation (CIC); Cystic Fibrosis; Synucleinopathy | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06460038 | Tenapanor | Phase 2 | Synucleinopathy | Neurology | Dec 2026 |
| NCT07382167 | Tenapanor | Phase 3 | Chronic Idiopathic Constipation (CIC) | Gastroenterology | Feb 2027 |
| NCT06810167 | Tenapanor | Phase 3 | Cystic Fibrosis | Respiratory | Jun 2027 |
Cash and short-term investments of $285m on 2026-09-30; operating cash outflow about $49m a year; runway about 70 months at that burn, to Jul 2032; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Trevi Therapeutics Zydus Therapeutics GRIN Therapeutics Rapport Therapeutics Incannex Healthcare
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.